In this study, a new active targeting strategy to favour ferrociphenol (FcdiOH) internalisation into brain tumour cells was developed by the use of lipid nanocapsules (LNCs) coated with a cell-internalising peptide (NFL-TBS.40-63 peptide)... more
In this study, a new active targeting strategy to favour ferrociphenol (FcdiOH) internalisation into brain tumour cells was developed by the use of lipid nanocapsules (LNCs) coated with a cell-internalising peptide (NFL-TBS.40-63 peptide) that interacts with tubulin-binding sites. In comparison, OX26 murine monoclonal antibodies (OX26-MAb) targeting transferrin receptors were also inserted onto the LNC surface. The incorporation of OX26 or peptide did not influence the in vitro antiproliferative effect of FcdiOH-LNCs on the 9L cells since their IC50 values were found in the same range. In vivo, intracerebral administration of OX26-FcdiOH-LNCs or peptide-FcdiOH-LNCs by convection enhanced delivery did not enhance the animal median survival time in comparison with untreated rats (25 days). Interestingly, intra-carotid treatment with peptide-FcdiOH-LNCs led to an ameliorated survival time of treated rats with the presence of animals surviving until days 35, 40 and 44. Such results were...
Delivery of therapeutic agents into the brain has been an ongoing challenge for many years. The poor prognosis for patient with primary malignant brain tumors treated with conventional techniques (surgery, radiotherapy and chemotherapy)... more
Delivery of therapeutic agents into the brain has been an ongoing challenge for many years. The poor prognosis for patient with primary malignant brain tumors treated with conventional techniques (surgery, radiotherapy and chemotherapy) has motivated the development of new strategies to deliver drugs into the brain. Local intracranial delivery of antineoplastic agents has appeared to be the most effective drug
